CalRx Biosimilar Insulin: California's Initiative to Enter the Insulin Market

被引：2
|
作者：
Feldman, Robin [1 ,2 ]
机构：
[1] Univ Calif San Francisco, Coll Law San Francisco, San Francisco, CA USA
[2] Univ Calif San Francisco, Coll Law San Francisco, 200 McAllister St, San Francisco, CA 94102 USA
来源：
JAMA INTERNAL MEDICINE | 2023年 / 183卷 / 10期
关键词：
D O I：
10.1001/jamainternmed.2023.3280
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This viewpoint evaluates California's CalRx Biosimilar Insulin Initiative, which aims to address insulin affordability by offering less expensive alternatives to existing products, specifically targeting patients with insulin-dependent diabetes.
引用
收藏
页码：1043 / 1044
页数：2
相关论文
共 50 条
  • [11] Hypersensitivity reaction to a biosimilar insulin glargine
    Garcia-Nares, Hector
    Leyva-Carmona, Maria Isabel
    Perez-Xochipa, Neftali
    Chiquete, Erwin
    JOURNAL OF DIABETES, 2015, 7 (02) : 155 - 157
  • [12] Biosimilar insulin as an alternative for the original products
    Lacka-Gazdzik, Beata
    Snit, Miroslaw
    Grzeszczak, Wladyslaw
    CLINICAL DIABETOLOGY, 2016, 5 (04): : 123 - 126
  • [13] The Biosimilar Insulin Landscape: Current Developments
    Lavalle-Gonzalez, Fernando J.
    Khatami, Hootan
    POSTGRADUATE MEDICINE, 2014, 126 (06) : 81 - 92
  • [14] Estimating Changes in Medicare Part D and Commercial Insurer Insulin Spending Amid Planned State-Led Biosimilar Insulin Production in California
    Anderson, Kelly E. E.
    Xuan, Andrew
    Anderson, Gerard F.
    Socal, Mariana P. P.
    JAMA INTERNAL MEDICINE, 2023, 183 (07) : 734 - 735
  • [15] Biosimilar Glargine Insulin: Implications for Prescribers and Patients
    Pereira, Katherine
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2017, 13 (03): : 236 - 237
  • [16] First Interchangeable Biosimilar Insulin Drug Is Approved
    Kuehn, Bridget M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (09): : 801 - 801
  • [17] FDA approves first interchangeable biosimilar insulin
    不详
    NURSE PRACTITIONER, 2021, 46 (09): : 56 - 56
  • [18] Patient and Educator Attitudes Toward Biosimilar Insulin
    Shivers, Joseph P.
    Brown, Adam S.
    Yarchoan, Mark
    Chang, Eric M.
    Kozak, Benjamin M.
    Wu, Vincent L.
    Rotenstein, Lisa S.
    Hirsch, Irl B.
    Wood, Richard
    Close, Kelly L.
    DIABETES, 2012, 61 : A316 - A316
  • [19] Administration of Biosimilar Insulin Analogs: Role of Devices
    Heinemann, Lutz
    Fritz, Ingo
    Khatami, Hootan
    Edelman, Steven V.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2017, 19 (02) : 79 - 84
  • [20] LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union
    Altman, Jean-Jacques
    Chevalier, Nicolas
    Delemer, Brigitte
    Travert, Florence
    Benabbad, Imane
    PRESSE MEDICALE, 2018, 47 (10): : 854 - 866
12345